Research Article
Clinical Study for Safety Evaluation of GXN Tablets Combined with Aspirin in Long-Term Treatment of Coronary Heart Disease
Table 1
Baseline characteristics.
| | Indicators | Experimental group (N = 2399) | Control group (N = 1187) |
| | Age (years) | 62.3 ± 8.9 | 62.2 ± 9.0 | | Female | 542 (22.6) | 280 (23.6) |
| | Nationality | | Han | 2357 (98.5) | 1142 (96.2) | | Others | 37 (1.5) | 45 (3.8) |
| | Height (cm) | 166.56 ± 7.59 | 166.46 ± 7.78 | | Weight (kg) | 70.48 ± 11.29 | 69.75 ± 11.41 | | BMI (kg/m2) | 25.35 ± 3.31 | 25.10 ± 3.28 | | Respiration (times/min) | 17.7 ± 1.8 | 18.3 ± 1.6 | | Resting heart rate (beats/min) | 68.8 ± 9.3 | 70.5 ± 9.6 | | Body temperature (°C) | 36.38 ± 0.32 | 36.52 ± 0.29 | | Systolic blood pressure (mmHg) | 129.2 ± 14.2 | 130.9 ± 13.8 | | Diastolic blood pressure (mmHg) | 77.5 ± 9.2 | 77.7 ± 9.4 |
| | Medical history | | History of current disease: PCI time | 36.27 ± 26.22 | 32.13 ± 22.36 | | History of current disease: 12 months after PCI | 2377 (99.7) | 1181 (99.9) | | History of allergy | 234 (9.8) | 103 (8.7) | | History of other diseases | 1873 (78.1) | 971 (81.8) |
| | Antiplatelet therapy after PCI | | Aspirin therapy | 2067 (87.2) | 1045 (89.8) | | Clopidogrel therapy | 1999 (84.3) | 935 (80.3) | | Ticagrelor therapy | 84 (3.5) | 137 (11.8) |
| | Syndrome of heart-blood stasis | 2379 (100.0) | 1161 (99.6) |
| | Heart function (NYHA grade) at enrollment | | I | 1530 (64.2) | 860 (73.6) | | II | 807 (33.9) | 306 (26.2) | | III | 46 (1.9) | 3 (0.3) | | IV | 0 (0.0) | 0 (0.0) |
|
|
